Increased activity of masteron hair loss, myalgia, myositis and rhabdomyolysis (rare) reported with protease inhibitors, particularly in combination with nucleoside reverse transcriptase inhibitors.
cases of osteonecrosis, especially in patients with recognized risk factors disease at a late stage or have been observed for a long time receiving combination antiretroviral therapy. The incidence of osteonecrosis is unknown.
Inflammatory immune reconstitution syndrome
In patients with HIV, and severe immune deficiency at the time of the start of combination antiretroviral therapy may experience an inflammatory reaction to asymptomatic or residual opportunistic infections.Also observed autoimmune diseases (such as Graves’ disease). However, the time to onset of the disease may vary, and such diseases may begin months after initiation of therapy.
Bleeding in patients with hemophilia
There was an increase in the frequency of spontaneous bleeding in patients with hemophilia receiving antiretroviral protease inhibitors.
Patients coinfected with hepatitis B and / or C
Patients with these infections often show increased activity of hepatic transaminases than patients without concomitant hepatitis B or C.
Information on acute overdose while taking the drug masteron hair loss in combination with ritonavir is limited in humans. Healthy volunteers received one dose of up to 3200 mg of darunavir in solution form and up to 1600 mg in tablets in combination with ritonavir are not observed with adverse effects.
A specific antidote is not known. In case of overdose should be general supportive therapy with monitoring of vital signs. Under appropriate indications for removal nevsosavsheysya drug to induce vomiting.It is also possible to use activated charcoal. Darunavir is primarily bound to plasma proteins, therefore, a significant removal of the active substance by dialysis is unlikely.
Interaction with other drugs
Darunavir used in combination with ritonavir, an inhibitor of isoenzyme and P-glycoprotein. Simultaneous use of a combination ritonavir and drugs that are metabolized mainly isoenzymes and transferred to P-glycoprotein, can cause increased concentrations of these drugs in the plasma, which in turn may be the cause of enhancing or prolonging the therapeutic effect, but also cause of side effects.
Recommendations for simultaneous use with other antiretroviral agents
The combination of drugs masteron hair lossritonavir (600/100 mg 2 times a day) did not have a clinically significant effect on the concentration of plasma dolutegravira. Comparison of the results of studies with historical pharmacokinetic data showed that dolutegravir has no clinically meaningful effect on the pharmacokinetics of darunavir. With simultaneous use of a combination ritonavir and dolutegravira does not require dose adjustment.
With simultaneous use of a combination ritonavir (600/100 mg 2 times a day) and elvitegravir, elvitegravir dose should be 150 mg 1 time per day.
Pharmacokinetic data and dosing recommendations when using other doses darunavir, and when used with a combination of elvitegravir / kobitsistat absent. Therefore, it is not recommended the simultaneous use of a combination ritonavir in doses different from 600/100 mg 2 times a day, and elvitegravir.
Not recommended simultaneous application of a combinationritonavir and elvitegravir in the presence of kobitsistata.
Based on the results of clinical studies have suggested that raltegravir may cause a slight decrease in darunavir plasma concentrations. Currently influence darunavir raltegravir concentration in plasma is not clinically significant. No dose adjustment is required masteron hair loss when combined with a low dose of ritonavir and raltegravir.